Takeda San Diego's Vice President to Present at Upcoming Symposium
Danbury, CT (October 13, 2010) – The Society for Biomolecular Sciences (SBS) announced that Dr. Daniel B. Kassel, Vice President of Analytical Sciences and DMPK at Takeda San Diego, Inc., will speak at the SBS Symposium on Tuesday, November 3, 2009 at the San Diego Marriott Mission Valley.
The two-day meeting, Advances and Challenges in Label-Free Technologies for Drug Discovery, will explore the latest scientific and technological advances in label-free technologies. Kassel’s presentation, Early ADME/Tox Profiling During Discovery Research, will focus on streamlined, high-throughput methods for data generation and data evaluation. “Dr. Kassel’s many years' experience in pharma and biotech immediately qualified him (as a speaker), and his particular interest and experience in label-free applied to profiling compounds ‘early and often’ matched well with a particular session focus,” said symposium program chair, Dr. Julio Martin of GlaxoSmithKline, Spain. “We are looking forward to hearing how Dr. Kassel and Takeda are learning from the application of label-free to their particular interests in DMPK.”
As Vice President of Analytical Sciences and DMPK at Takeda San Diego, Inc., his principal responsibilities include the development and implementation of state-of-the-art analytical and drug discovery technologies.
Prior to Takeda, San Diego, Kassel served as Senior Director of DuPont Pharmaceuticals Research Labs and before that, Director of Analytical Chemistry at CombiChem Inc. (acquired by DuPont) where he and his research team pioneered the design, development and implementation of automated preparative HPLC/MS. In addition, his team developed parallel HPLC/MS technologies, culminating in the issuance of two key patents in the area of parallel (indexed) spray mass spectrometry. Prior to Combichem Inc., Kassel held the positions of Senior Scientist, Research Investigator I and Research Investigator II at Glaxo Research Institute.
Kassel received his Ph.D. in Analytical Chemistry at Michigan State University in 1988 and held a post-doctoral fellowship at the Massachusetts Institute of Technology. He has been awarded an NIH National Research Service Award fellowship at Harvard University and has co-authored 60 peer-reviewed manuscripts and more than 100 abstracts. He also serves as a reviewer for numerous journals, and is editorial board member of Combinatorial Chemistry & High Throughput Screening and J. Combinatorial Chemistry.
Headquartered in Danbury, CT, the Society for Biomolecular Sciences (SBS) is the only international non-profit scientific society dedicated to drug discovery and its related disciplines. SBS was founded in 1994 to provide a forum for global education and information exchange among professionals in the chemical, pharmaceutical, biotech, and agrochemical industries. SBS members represent many of the largest and most influential research institutes, universities and pharmaceutical companies in the world, including the National Cancer Institute, University of California, Berkley, Harvard University, government agencies and organizations, and most major companies involved in drug discovery.